Company: IMRX
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001790340-25-000104
Chunk: 324

Company: Immuneering Corp
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 324
---
946)Other liabilities(23,957)(169,528)Net cash used in operating activities(23,526,762)(27,017,034)Cash flows from investing activities:  Purchases of property and equipment(11,061)(70,251)Maturities of marketable securities— 26,430,000 Net cash (used in) provided by investing activities(11,061)26,359,749 Cash flows from financing activities:  Proceeds from exercise of stock options2,055 732,458 Proceeds from issuance of common stock under employee stock purchase plan133,892 247,465 Proceeds from issuance of common stock under at-the-market offering, net of offering expenses13,676,667 — Payment of offering costs(64,013)— Net cash provided by financing activities13,748,601 979,923 Net (decrease) increase in cash and cash equivalents(9,789,222)322,638 Cash and cash equivalents at beginning of period36,144,720 59,405,817 Cash and cash equivalents at end of period$26,355,498 $59,728,455 

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

11

IMMUNEERING CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1 – Organization and Nature of Business

Immuneering Corporation, a Delaware corporation (“Immuneering” or the “Company”), was incorporated in 2008. Immuneering is a clinical-stage oncology company seeking to develop medicines for broad populations of cancer patients, with an initial aim to therapeutically address patients harboring RAS and/or RAF mutations. The Company aims to achieve broad activity through Deep Cyclic Inhibition® ("DCI") of the mitogen-activated protein kinase ("MAPK") pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate atebimetinib (also referred to as IMM-1-104) is in a Phase 1/2a clinical trial in patients with advanced solid tumors harboring RAS or RAF mutations. The Company is developing atebimetinib as a once-daily oral therapy through DCI of the MAPK pathway at the level of mitogen-activated protein kinase kinase ("MEK"). The Company’s development pipeline also includes early-stage programs.On October 30